Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2094133
Abstract: ABSTRACT Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we… read more here.
Keywords: recombination repair; hrd; homologous recombination; hrd pca ... See more keywords